These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 7048680)
1. [Treatment of obesity in general practice with femoxetine. A controlled clinical trial of the effects of femoxetine and placebo]. Kristensen JS; Christiansen P; Skrumsager BK Ugeskr Laeger; 1982 Mar; 144(13):939-42. PubMed ID: 7048680 [No Abstract] [Full Text] [Related]
2. Femoxetine in the treatment of obese patients in general practice. A randomized group comparative study with placebo. Bitsch M; Skrumsager BK Int J Obes; 1987; 11(2):183-90. PubMed ID: 3301710 [TBL] [Abstract][Full Text] [Related]
3. Double-blind comparison of efficacy, safety, and side effects of Bionamin, phentermine compound, and placebo in the treatment of exogenous obesity. Cohen A; De Felice EA; Leb SM; Fuentes JG; Rothwell KG; Truant AP Curr Ther Res Clin Exp; 1968 Jul; 10(7):323-34. PubMed ID: 4969672 [No Abstract] [Full Text] [Related]
4. [Therapeutic trial of an anorectic agent using the double blind cross-over technic]. Bienert HR; Uberla K Arzneimittelforschung; 1967 Mar; 17(3):336-42. PubMed ID: 4869817 [No Abstract] [Full Text] [Related]
5. [Therapy of obesity using appetite depressants]. Ikeda Y Nihon Naika Gakkai Zasshi; 1995 Aug; 84(8):1290-4. PubMed ID: 7594950 [No Abstract] [Full Text] [Related]
6. Preliminary clinical evaluation of a new appetite suppressant. A double-blind study. Feldman HS J Med Soc N J; 1966 Oct; 63(10):454-7. PubMed ID: 5341753 [No Abstract] [Full Text] [Related]
7. Double-blind comparison of placebo and 42-548, a new appetite suppressant, in obese volunteers. De Felice EA; Bronstein S; Cohen A Curr Ther Res Clin Exp; 1969 May; 11(5):256-62. PubMed ID: 4977396 [No Abstract] [Full Text] [Related]
13. Weight reduction with phenmetrazine and chlorphentermine a double-blind study. Hadler AJ Curr Ther Res Clin Exp; 1967 Nov; 9(11):563-9. PubMed ID: 4965505 [No Abstract] [Full Text] [Related]
14. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial. García-Morales LM; Berber A; Macias-Lara CC; Lucio-Ortiz C; Del-Rio-Navarro BE; Dorantes-Alvárez LM Clin Ther; 2006 May; 28(5):770-82. PubMed ID: 16861099 [TBL] [Abstract][Full Text] [Related]
15. [Clinical experimentation with fenproporex in the treatment of obesity. Apropos of 40 cases]. Warembourg H; Jaillard J Lille Med; 1968 Mar; 13(3):Suppl:273-6. PubMed ID: 4927185 [No Abstract] [Full Text] [Related]
16. A double-blind clinical trial of an appetite depressant, fenfluramine, in general practice. Brodbin P; O'Connor CA Practitioner; 1967 May; 198(187):707-10. PubMed ID: 4860039 [No Abstract] [Full Text] [Related]
17. [L-thyroxine propylhexedrine in the treatment of obesity. Crossed double blind study]. González Barranco J; Rull JA; Lozano Castañeda O Prensa Med Mex; 1974; 39(5-6):298-9. PubMed ID: 4612507 [No Abstract] [Full Text] [Related]
18. Sibutramine in pregnancy. Ramzi F; Elias D; Mona S; Zreik TG Eur J Obstet Gynecol Reprod Biol; 2005 Oct; 122(2):243-4. PubMed ID: 16219525 [No Abstract] [Full Text] [Related]
19. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial. Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225 [TBL] [Abstract][Full Text] [Related]